Latest news with #Shockwave
Yahoo
6 days ago
- Business
- Yahoo
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
Johnson & Johnson JNJ is one of the few large drug and medical device companies with a presence in both the pharmaceuticals as well as medical devices segments. J&J's medical devices segment, called MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues. Sales in the MedTech segment rose 4.1% on an operational basis in the first quarter of 2025, driven by new product uptake and commercial execution, and contributions from the recent acquisitions of Shockwave and Abiomed. However, sales in J&J's MedTech business continue to face headwinds in the Asia Pacific, particularly in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anticorruption campaign. VBP is a government-driven cost-containment effort in China. In the MedTech segment, recent acquisitions of Shockwave and Abiomed, as well as continued uptake of its new products, are likely to drive growth in 2025. However, J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses, such as PFA ablation catheters in U.S. electrophysiology. JNJ expects continued impacts from VBP issues in China in 2025 as VBP expands across provinces and products. Nonetheless, sales are expected to be higher in the second half of 2025 than in the first half as the business moves past tougher first-quarter comps and new products gain momentum throughout 2025. However, tariff-related costs are expected to hurt profits in the MedTech segment J&J's MedTech unit faces strong competition from several major players in the medical device industry like Medtronic MDT, Abbott, Stryker SYK and Boston Scientific BSX. While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker Corporation is a global leader in medical technology, specializing in innovative solutions across surgical, neurotechnology, orthopedics and spine care. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical device products across cardiovascular, diagnostics, and diabetes care. J&J's shares have outperformed the industry year to date. The stock has risen 7.1% in the year-to-date period against a 0.4% decline of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.12 forward earnings, lower than 14.92 for the industry. The stock is also trading below its five-year mean of 15.74. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.60 per share over the past 60 days, while that for 2026 has declined from $11.00 to $10.98 over the same timeframe. Image Source: Zacks Investment Research J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Globe and Mail
6 days ago
- Business
- Globe and Mail
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
Johnson & Johnson JNJ is one of the few large drug and medical device companies with a presence in both the pharmaceuticals as well as medical devices segments. J&J's medical devices segment, called MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues. Sales in the MedTech segment rose 4.1% on an operational basis in the first quarter of 2025, driven by new product uptake and commercial execution, and contributions from the recent acquisitions of Shockwave and Abiomed. However, sales in J&J's MedTech business continue to face headwinds in the Asia Pacific, particularly in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anticorruption campaign. VBP is a government-driven cost-containment effort in China. In the MedTech segment, recent acquisitions of Shockwave and Abiomed, as well as continued uptake of its new products, are likely to drive growth in 2025. However, J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. Competitive pressure is also hurting sales growth in some MedTech businesses, such as PFA ablation catheters in U.S. electrophysiology. JNJ expects continued impacts from VBP issues in China in 2025 as VBP expands across provinces and products. Nonetheless, sales are expected to be higher in the second half of 2025 than in the first half as the business moves past tougher first-quarter comps and new products gain momentum throughout 2025. However, tariff-related costs are expected to hurt profits in the MedTech segment J&J's Key Competitors in the Medical Devices Market J&J's MedTech unit faces strong competition from several major players in the medical device industry like Medtronic MDT, Abbott, Stryker SYK and Boston Scientific BSX. While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker Corporation is a global leader in medical technology, specializing in innovative solutions across surgical, neurotechnology, orthopedics and spine care. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical device products across cardiovascular, diagnostics, and diabetes care. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 7.1% in the year-to-date period against a 0.4% decline of the industry. From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.12 forward earnings, lower than 14.92 for the industry. The stock is also trading below its five-year mean of 15.74. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.60 per share over the past 60 days, while that for 2026 has declined from $11.00 to $10.98 over the same timeframe. J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report
Hindustan Times
22-06-2025
- Automotive
- Hindustan Times
Auto recap, June 21: Lexus NX 350h Overtrail review, Tesla India business, Ultraviolette EV bookings
Here is your quick check on the biggest developments in the world of automobiles. (AFP) Notify me The automotive sector is undergoing swift transformations, making it challenging to keep up with all the recent developments. At HT Auto, we are committed to providing the most pertinent and up-to-date information as it emerges. Presented below is a brief summary of the main highlights from Saturday, June 21. Lexus NX 350h Overtrail review: For the sophisticated adventurer Launched in April 2024, the Lexus NX 350h Overtrail blends luxury with a mild adventurous streak. With its unique Moon Desert paint and trim exclusive features, this hybrid SUV aims to be more than just a luxurious commuter. This Japanese SUV reveals its character gradually, from bold design choices to surprising driving behaviour. But does it really prove all that it claims? Here's our in-depth take after testing the car for over 1,000 km over 4 days. Also Read : Lexus NX 350h Overtrail Review: For the sophisticated adventurer Ultraviolette bags over 60,000 bookings for Tesseract, 7,000 for Shockwave Ultraviolette Automotive will enter the mass-market electric two-wheeler space next year, and the company has garnered strong interest from buyers nearly a year before deliveries. The manufacturer has revealed that its maiden electric scooter, Tesseract, has garnered over 60,000 bookings, while the Shockwave electric off-roader has bagged 7,000 bookings so far. Both models are slated for delivery in the first quarter of 2026. Also Read : Ultraviolette bags over 60,000 bookings for Tesseract, 7,000 for Shockwave Revolt Motors rolls out 50,000th electric motorcycle from Haryana plant Revolt Motors has announced the rollout of its 50,000th electric motorcycle from the brand's production facility in Manesar, Haryana. One of the first movers in the electric two-wheeler space, the company began operations in August 2019 and initially retailed the RV400 electric motorcycle. Revolt's range now comprises the RV400, RV1+, and RV BlazeX e-bikes. Also Read : Revolt Motors rolls out 50,000th electric motorcycle from Haryana plant Tesla to open India showrooms in July with Model Y Tesla Inc. is officially gearing up to enter the Indian automotive market, with plans to open its first showrooms in July 2025. According to sources close to the matter, the electric vehicle pioneer will debut its presence in Mumbai by mid-July, followed by a second showroom in New Delhi shortly after. This long-anticipated move will mark the company's formal entry into the world's third-largest car market. The American EV giant has begun importing its flagship Model Y rear-wheel drive SUVs from its Shanghai plant, signalling the start of its retail operations in India. Bloomberg News reviewed official import documents that confirm the arrival of at least five Model Y vehicles at the Mumbai port. These units were declared at ₹ 27.69 lakh (approx. $31,988), with over ₹ 21 lakh levied in import duties, reflecting India's high tariffs on completely built units. Also Read : Tesla to open India showrooms in July with Model Y Royal Enfield Urbanite Hoodie Review: Stylish Urban Riding Gear for Everyday Commutes When it comes to riding gear, Royal Enfield has made a name for blending style with practicality. The Urbanite Hoodie, one of the brand's more lifestyle-oriented offerings, promises comfort, safety, and urban flair. We got our hands on this hoodie for a test in Delhi's demanding riding environment, where dust, traffic, and fluctuating temperatures create unique challenges for motorcyclists. Also Read : Royal Enfield Urbanite Hoodie Review: Stylish Urban Riding Gear for Everyday Commutes No fuel for end-of-life petrol and diesel vehicles in Delhi from July 1 All end-of-life (EoL) vehicles in Delhi will not be allowed to refuel at fuel stations starting from July 1, 2025. The Commission for Air Quality Management (CAQM) has announced the new initiative to crack down on EoL vehicles still plying in the national capital, contributing to the worsening air quality in the region. The EoL vehicles will be identified with the help of the Automatic Number Plate Recognition (ANPR) cameras installed at fuel stations across Delhi. Also Read : No fuel for end-of-life petrol and diesel vehicles in Delhi from July 1 Get insights into Upcoming Cars In India, Electric Vehicles, Upcoming Bikes in India and cutting-edge technology transforming the automotive landscape. First Published Date: 22 Jun 2025, 09:01 AM IST
Hindustan Times
21-06-2025
- Automotive
- Hindustan Times
Ultraviolette bags over 60,000 bookings for Tesseract, 7,000 for Shockwave
Ultraviolette bagged 50,000 bookings for the Tesseract by March, while the next 10,000 have been achieved in the last quarter Check Offers Ultraviolette Automotive will enter the mass-market electric two-wheeler space next year and the company has garnered strong interest from buyers nearly a year before deliveries. The manufacturer has revealed that its maiden electric scooter Tesseract has garnered over 60,000 bookings, while the Shockwave electric off-roader has bagged 7,000 bookings so far. Both models are slated for delivery in the first quarter of 2026. Ultraviolette Tesseract: What You Need To Know The Ultraviolette Tesseract will arrive as a sporty iteration of a scooter, promising a host of features including several segment firsts. The company announced the model at an introductory price of ₹ 1.20 lakh for the first 50,000 customers. Notably, the brand had to extend the introductory price owing to an overwhelming demand. The prices currently start from ₹ 1.45 lakh onwards. All prices are ex-showroom. Ultraviolette secured 50,000 bookings till March this year, while the next 10,000 have been achieved in the last quarter. While complete specifications are yet to be revealed, the Ultraviolette Tesseract will come with a 3.5kWh battery pack on the base trim, while the higher variants will get 5 kWh and 6 kWh options. The feature pack is equally fancy with wireless charging, radar system at the front and rear, rearview mirrors with blindspot detection, front and rear radar, a dashcam, and more. The model promises a top speed of 125 kmph and will come with traction control, dual-channel ABS, four-level regen, and hill hold. Based on a new Light Motorcycle platform called 'Funduro', the new Shockwave is an electric enduro bike Ultraviolette Shockwave: What You Need To Know The Shockwave is an electric enduro machine that was launched at an inteoductor price of ₹ 1.50 lakh for the first 1,000 customers. Prices now start at ₹ 1.75 lakh (ex-showroom). The Shockwave packs an electric motor churning out 14.5 bhp, while power will come from a 4 kWh battery pack with a claimed range of 165 km (IFC) on a single charge. UV says the electric enduro can sprint from 0-60 kmph in 2.9 seconds and has a top speed of 120 kmph. On the feature front, the bike will come with all-LED lighting, a steel frame, telescopic front forks and a monoshock at the rear, all while riding on 21-inch front and 17-inch rear spoked wheels. The Shockwave will also pack switchable dual-channel ABS, four-level traction control, and six-level regen. Check out Upcoming EV Bikes in India. First Published Date: 21 Jun 2025, 12:35 PM IST
Hindustan Times
03-06-2025
- Automotive
- Hindustan Times
Ultraviolette Shockwave design patent filed. Check out what's different
Ultraviolette Shockwave has a top speed of 120 kmph. Check Offers Ultraviolette has filed a design patent for its upcoming electric off-roader - Shockwave. The dirt bike is expected to go on sale in 2026, and now with the patent filed, the manufacturer wants to protect the design of the upcoming motorcycle. The prototype of the Shockwave was unveiled back in March, and in the design patent, it can be seen that a few changes have been made. The patent reveals that the manufacturer will forgo the extravagant fork covers and brake lever guards that were present in the concept design. Additionally, the patent illustration excludes crucial components such as the headlight, tail light, and turn signals, suggesting the possibility of a track-exclusive version or several variants under development, where there is one model that is road legal while the other one is not. What is the price of the Ultraviolette Shockwave? Ultraviolette Shockwave is priced at ₹ 1.75 lakh ex-showroom. Earlier, the prices were ₹ 1.50 lakh ex-showroom for the first 1,000 customers. The pre-bookings for the e-enduro motorcycle are already open, and deliveries are slated to begin in the first quarter of 2026. Ultraviolette Shockwave has a claimed IDC range of 165 km. What are the specifications of the Ultraviolette Shockwave? The latest Shockwave is equipped with a 14.5 bhp electric motor that delivers a peak torque of 505 Nm at the wheel. According to UV, it can reach a maximum speed of 120 km/h, accelerating from 0 to 60 km/h in just 2.9 seconds. Weighing in at 120 kg, the company has yet to specify whether this weight is dry or kerb. UV asserts that the new Shockwave will provide a range of 165 km (IDC) on a single charge, powered by a 4 kWh battery pack. Also Read : Ultraviolette Tesseract electric scooter debuts promising 261 km range, priced at ₹ 1.45 lakh What is the hardware of the Ultraviolette Shockwave? The newly introduced Ultraviolette Shockwave marks the first of two motorcycles unveiled on the brand's innovative 'Light Vehicle' platform, known as 'Funduro.' The suspension system features 37 mm cartridge-type telescopic front forks offering 200 mm of travel, while the rear is equipped with a monoshock providing 180 mm of travel. This electric enduro is fitted with a 19-inch front wheel paired with a 90/90 section tyre. The rear wheel measures 17 inches and is fitted with a 110/90 section tyre. Both wheels are of the spoked variety. The braking system is comprised of a 270 mm front disc paired with an axial-mounted dual-piston caliper, while the rear features a 220 mm disc with a floating piston caliper. Check out Upcoming EV Bikes in India. First Published Date: 03 Jun 2025, 12:05 PM IST
